Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Phase 2

Completed

• Conditions: Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
• Interventions: Drug: Bevacizumab; Drug: Cetuximab; Drug: L-OHP; Drug: l-LV; Drug: 5-FU

• Registration Number: NCT01836653
• Lead Sponsor: EPS Corporation

Brief Summary

The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.

Detailed Description

Description: The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.

Study Timeline

• Study First Submitted: 2013-04-14
• Study First Submitted QC: 2013-04-19
• Study First Posted: 2013-04-22
• Study Start: 2013-05
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-01
• Last Update Posted: 2017-08-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

1. Histopathologically confirmed colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.

2. RAS wild type

3. Synchronous* or metachronous liver limited meitastasis with no extrahepatic desiease

   • shychronous liver limited metastasis with primary lesion less than two thirds of the circumference
   • patients with primary lesion more than two thirds of the circumference can be enrolled after primary resection

4. Patients who has one or more lesion(s) of diameter 1 cm or larger (RECEST v1.1) be able to assess continuously on the basis of the protocol by contrast enhanced CT or contrast enhanced MRI of the liver:

(1)Liver metastases 5 or more (2)Liver metastases with 5 cm or larger in greatest dimension (3)Unresectable considering remaining hepatic function (4)Invasion into all hepatic veins or inferior vena cava (5)Invasion into both right and left hepatic arteries or portal veins 5.No prior chemotherapy for colorectal cancer including hepatic arterial infusion. Excluding postoperative and preoperative chemoradiotherapy except for rectal cancer with synchronous liver metastases. Patients received postoperative chemotherapy containing oxaliplatin have to be enrolled after 24 weeks from the last oxaliplatin administration.

6.No previous treatment including ablation therapy, cryotherapy and chemotherapy for metastases 7.Age at enrollment is >=20 and =<80 years 8.The Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 9.Life expectancy from the day of enrollment is 3 months or longer 10.Major organ functions less than 14 days prior to entry meet the following criteria.

1. Neu >= 1500/mm3
2. Pt >= 10.0x10^4/mm3
3. Hb >= 9.0 g/dL
4. T-bil =< 2.0 mg/dL
5. AST and ALT =< 200 IU/L
6. sCr =< 1.20 mg/dL
7. INR < 1.5
8. Proteinuria =< 2+ 11.Written informed consent

Exclusion Criteria

1. Previously experienced severe allergic reaction to drugs
2. Receiving anti-platelet drugs (aspirin >= 325 mg/day) or NSAIDs
3. Receiving chronic systemic corticosteroid treatment
4. Surgery/ biopsy with skin incision or traumatic injury with suture less than 14 days prior to entry. Excluding, suture for implanted venous reservoirs with catherter is allowed.
5. Severe postoperative complications (e.g. postoperative infection, anastomic dehiscence or paralytic ileus)
6. Diagnosed as hereditary colorectal cancer
7. Active other malignancies
8. Cerebrovascular disease or symptoms less than 1 year prior to entry
9. Pleural effusion, ascites or cardiac effusion requiring drainage
10. Hemorrhage/bleeding, paralytic ileus, obstruction or ulceration of gastrointestinal tract
11. Perforation of gastrointestinal tract less than 1 year prior to entry
12. Presence of active infection
13. HBs antigen or HCV antibody positive
14. Uncontrolled comorbidity including hypertension, diabetes, arrhythmia, or other diseases (such as cardiac disorder, interstitial pneumonia or renal disorder)
15. Presence of >= grade 2 diarrhea
16. Presence of >= grade 1 peripheral neuropathy
17. Pregnant or lactating women. Women and men with childbearing potential unwilling to use effective means of contraception
18. Psychosis or psychiatric symptoms who are not able to comply with the protocol
19. Any other medical conditions disable to comply with the protocol

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
mFOLFOX + Bmab	Bevacizumab	mFOLFOX plus bevacizumab
mFOLFOX + Bmab	L-OHP	mFOLFOX plus bevacizumab
mFOLFOX + Cmab	Cetuximab	mFOLFOX plus cetuximab
mFOLFOX + Cmab	l-LV	mFOLFOX plus cetuximab
mFOLFOX + Bmab	l-LV	mFOLFOX plus bevacizumab
mFOLFOX + Bmab	5-FU	mFOLFOX plus bevacizumab
mFOLFOX + Cmab	L-OHP	mFOLFOX plus cetuximab
mFOLFOX + Cmab	5-FU	mFOLFOX plus cetuximab

Primary Outcome Measures

Name	Time	Method
Progression-free survival	assessed every 8 weeks, up to 4 years	assessed by Independent Review Committee

Secondary Outcome Measures

Name	Time	Method
Response rate	assessed every 8 weeks, up to 4 years

Trial Locations

Locations (1)

EPS Corporation; 🇯🇵 Shinjuku-ku, Tokyo, Japan